Casey v. MERCK & CO., INC.

653 F.3d 95, 2011 U.S. App. LEXIS 16151, 2011 WL 3375104
CourtCourt of Appeals for the Second Circuit
DecidedAugust 5, 2011
DocketDocket 10-1137-cv(L), 10-1196-cv (Con), 10-1150-cv (Con), 10-1149-cv (Con)
StatusPublished
Cited by37 cases

This text of 653 F.3d 95 (Casey v. MERCK & CO., INC.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Second Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Casey v. MERCK & CO., INC., 653 F.3d 95, 2011 U.S. App. LEXIS 16151, 2011 WL 3375104 (2d Cir. 2011).

Opinion

LOHIER, Circuit Judge:

This consolidated appeal involves questions of Virginia law relating to equitable and statutory cross-jurisdictional tolling, and in particular whether Virginia law recognizes the tolling doctrine established in American Pipe & Construction Company v. Utah, 414 U.S. 538, 94 S.Ct. 756, 38 L.Ed.2d 713 (1974).

The plaintiffs in these four cases appeal from a judgment of the United States District Court for the Southern District of New York (Keenan, J.), granting summary judgment in favor of defendant Merck Sharp & Dohme Corporation (“Merck”), formerly known as Merck & Co., Inc., and dismissing their product liability claims for injuries allegedly caused by Merck’s prescription drug, Fosamax. 1 The plaintiffs filed their separate lawsuits in the Southern District of New York based on diversity jurisdiction under 28 U.S.C. § 1332.

*97 The plaintiffs, all residents of Virginia, raise only state law claims and do not dispute either that Virginia’s two-year statute of limitations applies to their claims or that they filed their actions more than two years after they were first injured. Instead, they argue that the statute of limitations was tolled by the pendency of a federal class action filed in the United States District Court for the Middle District of Tennessee on September 15, 2005, which alleged similar injuries and raised similar claims. In particular, the plaintiffs argue that the “rule” of American Pipe should apply, and, accordingly, that the statute of limitations should have been tolled from September 2005 until the motion for class certification was denied in that case in January 2008 — in other words, for some 28 months.

The District Court rejected the plaintiffs’ argument that American Pipe applied to their claims and concluded instead that Virginia law controlled the timeliness of the action. Relying on the Fourth Circuit’s decision in Wade v. Danek Medical, Inc., 182 F.3d 281 (4th Cir.1999), which predicted that the Supreme Court of Virginia would reject tolling for federal class actions filed in foreign jurisdictions, the District Court held that Virginia law did not permit tolling of a state statute of limitations due to the pendency of a class action filed in another jurisdiction. See In re Fosamax Prods. Liab. Litig., 694 F.Supp.2d 253, 258 (S.D.N.Y.2010). We agree with the District Court that Virginia law governs the question of whether the plaintiffs’ claims were tolled pending the Tennessee class action. But, both Wade itself, and state and federal court decisions in Virginia since Wade, leave us less certain whether equitable or statutory cross-jurisdictional tolling is available under Virginia law. Accordingly, we certify the following two questions to the Supreme Court of Virginia and stay resolution of these cases in the interim:

(1) Does Virginia law permit equitable tolling of a state statute of limitations due to the pendency of a putative class action in another jurisdiction?

(2) Does Va.Code Ann. § 8.01-229(E)(1) permit tolling of a state statute of limitations due to the pendency of a putative class action in another jurisdiction?

BACKGROUND

Fosamax is a prescription drug manufactured by Merck that falls within a class of drugs known as bisphosphonates, which are commonly used to treat bone conditions such as osteoperosis. Fosamax is a nitrogenous bisphosphonate, and nitrogenous bisphosphonates have allegedly been linked to osteonecrosis — bone death — of the jaw. Plaintiff Rebecca Quarles was prescribed and took Fosamax for roughly six months starting in 2002. She was diagnosed with osteonecrosis of the jaw and failure of dental implants on October 31, 2003, and sued Merck on December 17, 2007. Dorothy Deloriea was prescribed and took Fosamax in 1999, and developed osteomyelitis and osteonecrosis of the jaw in 2004. She commenced her action against Merck on November 12, 2008. Ora Casey was prescribed and took Fosamax for four years, beginning in July 2000. She was diagnosed with osteonecrosis of the jaw in 2004, and died three years later, in December 2007. Casey’s estate initiated this action on January 25, 2008. Roberta Brodin was prescribed and took Fosamax beginning in February 2001 and was diagnosed with osteonecrosis of the jaw in 2005. She initiated her action on May 1, 2007.

Quarles, Deloriea, Casey, and Brodin each sued Merck in separate actions in the Southern District of New York, raising exclusively Virginia state law claims. The *98 actions asserted diversity of citizenship as the basis for federal jurisdiction and alleged common claims for strict liability, failure to warn, breach of express and implied warranty, and negligence in the design, testing, development, manufacture, labeling, marketing, distribution and sale of Fosamax. 2

In September 2005, before the plaintiffs filed these cases, a putative class action asserting substantially identical claims on behalf of a nationwide class of Fosamax users was filed in the Middle District of Tennessee. That action, Wolfe v. Merck, was transferred to the Southern District of New York by the Judicial Panel on Multidistrict Litigation. 3 The District Court denied the motion to certify the class in Wolfe v. Merck on January 28, 2008. See In re Fosamax Prods. Liab. Litig., No. 1:06-md-01789 (S.D.N.Y. Jan. 28, 2008) (order denying class certification). At least for purposes of this appeal, Merck concedes that the plaintiffs would have been members of the certified class had the certification motion been granted by the District Court.

On June 23, 2009, Merck moved for summary judgment against all three plaintiffs, arguing that New York’s borrowing statute required application of Virginia’s two-year statute of limitations. Merck further argued that, because the plaintiffs’ complaints were all filed more than four years after they allegedly sustained their injuries, their claims were time-barred.

Citing American Pipe, the plaintiffs responded that their claims were timely because Virginia’s two-year statute of limitations was tolled for 28 months during the pendency of the Wolfe class action, until the District Court denied class certification. The plaintiffs argued that, under American Pipe, which involved federal claims and a federal statute of limitations, the filing of a putative class action tolls the limitations period for absent class members, regardless of whether the claims of absent members arise under federal or state law or whether the applicable state’s law permits tolling.

On March 15, 2010, the District Court granted Merck’s summary judgment motion. See In re Fosamax Prods. Liab. Litig., 694 F.Supp.2d 253 (S.D.N.Y.2010).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Wilkins v. Genzyme Corporation
93 F.4th 33 (First Circuit, 2024)
WILKINS v. GENZYME CORPORATION
D. Massachusetts, 2022
Nunes v. Cable News Network, Inc.
31 F.4th 135 (Second Circuit, 2022)
Conn. Gen. Life Ins. Co. v. BioHealth Labs., Inc.
988 F.3d 127 (Second Circuit, 2021)
Perrow v. District of Columbia
District of Columbia, 2020
Kim v. Harte Hanks, Inc.
S.D. New York, 2019
Boykins v. City of Syracuse
N.D. New York, 2019
Tobias Bermudez Chavez v. Occidental Chemical Corp.
933 F.3d 186 (Second Circuit, 2019)
Wilchfort v. Knight
307 F. Supp. 3d 64 (E.D. New York, 2018)
In re Libor-Based Fin. Instruments Antitrust Litig.
299 F. Supp. 3d 430 (S.D. Illinois, 2018)
Chavez v. Occidental Chem. Corp.
300 F. Supp. 3d 517 (S.D. Illinois, 2018)
Boelter v. Hearst Communications, Inc.
269 F. Supp. 3d 172 (S.D. New York, 2017)
Pergament v. Tracey (In re Thilman)
557 B.R. 294 (E.D. New York, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
653 F.3d 95, 2011 U.S. App. LEXIS 16151, 2011 WL 3375104, Counsel Stack Legal Research, https://law.counselstack.com/opinion/casey-v-merck-co-inc-ca2-2011.